Patient symptomatology | Recommendations for alglucosidase alfa ERT |
---|---|
Presymptomatic with no signs or symptoms | ERT not necessary. Patient should be monitored every 6Â months and ERT initiated if there is evidence of clinical deterioration |
Presymptomatic with abnormal muscle imaging or abnormal muscle biopsy | ERT should be considered on a case-by-case basis |
Symptomatic with signs or symptoms | ERT should be initiated in patients with muscle weakness or reduced pulmonary function |
Patients with markedly advanced disease, who have lost ambulation and are ventilation-dependent | ERT should be administered for 1Â year with evaluation of effectiveness |